Room for improvement in draft medicines policy, says Medicines Australia

26 September 2022

Australia’s National Medicines Policy (NMP) Review started in August 2021 but was paused until after the Federal Election to allow stakeholders more time to provide feedback.

Commenting on the situation, Elizabeth de Somer, chief executive of trade group Medicines Australia, said the new draft of the NMP – which was released under the new Minister for Health and Aged Care, Mark Butler – is an improvement from the original draft.

"The NMP must remain future-fit and set us up for the innovative medicines and treatments that are just on the horizon"“The latest draft of the National Medicines Policy is strides ahead of the previous version and shows the Committee and Minister have heard the concerns of key stakeholders including the medicines industry, health experts and patients,” she said.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK